Zacks: Brokerages Expect REGENXBIO Inc. (NASDAQ:RGNX) to Announce -$1.57 EPS

Equities research analysts expect that REGENXBIO Inc. (NASDAQ:RGNXGet Rating) will announce earnings of ($1.57) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for REGENXBIO’s earnings, with estimates ranging from ($1.60) to ($1.56). REGENXBIO posted earnings of ($1.36) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 15.4%. The firm is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that REGENXBIO will report full-year earnings of ($4.47) per share for the current year, with EPS estimates ranging from ($6.52) to ($1.72). For the next year, analysts anticipate that the firm will post earnings of ($2.68) per share, with EPS estimates ranging from ($6.28) to $1.80. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow REGENXBIO.

REGENXBIO (NASDAQ:RGNXGet Rating) last issued its earnings results on Tuesday, March 1st. The biotechnology company reported $6.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $2.39. REGENXBIO had a return on equity of 17.92% and a net margin of 21.38%. The business had revenue of $398.66 million during the quarter, compared to the consensus estimate of $255.76 million. During the same period last year, the company earned ($1.24) EPS. The company’s revenue for the quarter was up 1759.0% on a year-over-year basis.

A number of analysts recently issued reports on the company. TheStreet downgraded REGENXBIO from a “c” rating to a “d+” rating in a research report on Monday, May 16th. Morgan Stanley cut their price objective on REGENXBIO from $51.00 to $47.00 and set an “overweight” rating for the company in a research report on Tuesday. SVB Leerink cut their price objective on REGENXBIO from $29.00 to $25.00 and set a “market perform” rating for the company in a research report on Wednesday, March 2nd. Zacks Investment Research cut REGENXBIO from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Chardan Capital restated a “buy” rating on shares of REGENXBIO in a report on Monday, April 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, REGENXBIO presently has an average rating of “Hold” and a consensus price target of $45.38.

Shares of NASDAQ:RGNX traded up $0.10 during midday trading on Wednesday, reaching $19.45. 278,221 shares of the company’s stock were exchanged, compared to its average volume of 416,379. The firm’s 50 day simple moving average is $27.85 and its two-hundred day simple moving average is $29.03. The stock has a market cap of $838.96 million, a price-to-earnings ratio of 9.05 and a beta of 1.12. REGENXBIO has a fifty-two week low of $18.69 and a fifty-two week high of $46.46.

Institutional investors and hedge funds have recently made changes to their positions in the company. Voya Investment Management LLC lifted its stake in REGENXBIO by 1.2% during the third quarter. Voya Investment Management LLC now owns 26,186 shares of the biotechnology company’s stock worth $1,098,000 after purchasing an additional 314 shares during the last quarter. New York State Teachers Retirement System lifted its stake in REGENXBIO by 0.9% during the fourth quarter. New York State Teachers Retirement System now owns 45,631 shares of the biotechnology company’s stock worth $1,492,000 after purchasing an additional 400 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in REGENXBIO by 8.0% during the first quarter. Teacher Retirement System of Texas now owns 6,589 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 487 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in REGENXBIO by 3.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,443 shares of the biotechnology company’s stock worth $472,000 after buying an additional 488 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in REGENXBIO by 5.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,890 shares of the biotechnology company’s stock worth $328,000 after buying an additional 532 shares during the period. Institutional investors and hedge funds own 87.57% of the company’s stock.

REGENXBIO Company Profile (Get Rating)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Recommended Stories

Get a free copy of the Zacks research report on REGENXBIO (RGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.